Skip to main content

Heron Therapeutics, Inc.

corporate_fare Company Profile

Heron Therapeutics, Inc.

HRTX·NASDAQ·Life Sciences·CIK 0000818033

We are a commercial-stage biotechnology company focused on developing and selling therapeutic innovations to improve medical care for patients. Our approach to drug discovery and development has resulted in a portfolio of products for acute care and oncology patients. Our acute care product portfolio includes ZYNRELEF, a dual-acting local anesthetic. ZYNRELEF combines bupivacaine and a low dose of meloxicam. The FDA classified ZYNRELEF as an extended-release product, noting that Phase 3 studies showed it significantly reduced pain and increased the proportion of patients needing no opioids for the first 72 hours after surgery, compared to bupivacaine solution. ZYNRELEF received initial FDA approval in May 2021, and U.S. commercial sales began in July 2021. The FDA expanded ZYNRELEF's indication in December 2021 and January 2024. It is approved for adults for postsurgical pain relief for up to 72 hours after soft tissue and orthopedic surgical procedures, including foot and ankle, and other orthopedic procedures where direct exposure to articular cartilage is avoided. In September 2024, the FDA approved the ZYNRELEF Vial Access Needle ("VAN"), which is replacing the current vented vial spike. Through March 31, 2025, ZYNRELEF was reimbursed outside the surgical bundle payment in the Hospital Outpatient Department ("HOPD") setting via pass-through status from the Centers for Medicare and Medicaid Services ("CMS"). Effective April 1, 2025, ZYNRELEF is reimbursed through the Non-Opioids Prevent Addiction in the Nation ("NOPAIN") Act, which directs CMS to provide separate Medicare reimbursement for non-opioid pain treatments used in hospital outpatient departments or ambulatory surgical centers.

Heron Therapeutics, Inc. (NASDAQ:HRTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for HRTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 13 rated 8 or above. Recent SEC coverage for HRTX spans 10-Q, 8-K, DEFA14A, DEF 14A.

Recent high-impact activity:

  • Heron 10-Q: Q3 Revenue $35.3M, $23.4M Cash, Going-Concern Warning Absent CorMedix Deal
  • Heron Posts $35.3M Q3 Revenue, Down 7.8%, With No 2026 Outlook
  • Heron Posts Q3 Revenue of $35.3M, Down 7.8%, as CorMedix Asset Sale Looms
  • Heron Sells Substantially All Assets to CorMedix for $145M Cash Plus 14.58M Shares
  • Heron Withdraws 2026 Guidance as CINVANTI Patent Loss Clouds Outlook

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$154.9M
Net Income
-$20.2M
Diluted EPS
-$0.12
Op. Cash Flow
-$27.59M
Free Cash Flow
-$27.91M
Gross Profit
$113.56M
Operating Income
-$2.54M
Cash & Equivalents
$28.65M
Debt / Equity
0.00×
Net Margin
-13.0%
Shares Outstanding
188.31M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-073515

Short Interest & Short Volume

19.54 days to cover

FINRA reported short interest of 34,004,069 shares in HRTX as of the October 30, 2026 settlement, a 7.4% decrease from the prior period — about 19.5 days to cover at its recent average daily volume. On November 20, 2026, 57.5% of HRTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)34,004,069 shares as of October 30, 2026
Change vs prior period▼ 7.4%
Days to cover19.54 at avg daily volume of 1,740,088
Daily short volume (FINRA facilities)57.5% of 730,033 shares on November 20, 2026
5-day average short volume29.9%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with H →
$0.25 -0.99% today
52-week range · as of 2026-11-09 $0.25 – $1.57
Market cap
$48.04M
Volume
1.8M (0.2× avg)
3-mo avg 7.1M
Live data · 2026-11-22 12:40 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HRTX - Latest Insights

HRTX
Nov 09, 2026, 8:50 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.3924
Real-time Price: $0.250 info
Change: -$0.1424 (-36%) info
Market Cap: $48.044M info
HRTX
Nov 09, 2026, 8:30 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.4055
Real-time Price: $0.250 info
Change: -$0.1555 (-38%) info
Market Cap: $48.044M info
HRTX
Nov 09, 2026, 8:15 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.3792
Real-time Price: $0.250 info
Change: -$0.1292 (-34%) info
Market Cap: $48.044M info
HRTX
Nov 09, 2026, 7:40 AM EST
Filing Type: 8-K
Importance Score:
10
Price at Filing: $0.3841
Real-time Price: $0.250 info
Change: -$0.1341 (-35%) info
Market Cap: $48.044M info
HRTX
Aug 17, 2026, 7:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.3408
Real-time Price: $0.250 info
Change: -$0.0908 (-27%) info
Market Cap: $48.044M info
HRTX
Aug 10, 2026, 8:00 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.4307
Real-time Price: $0.250 info
Change: -$0.1807 (-42%) info
Market Cap: $48.044M info
HRTX
Aug 10, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.4201
Real-time Price: $0.250 info
Change: -$0.1701 (-40%) info
Market Cap: $48.044M info
HRTX
Jun 25, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.410
Real-time Price: $0.250 info
Change: -$0.160 (-39%) info
Market Cap: $48.044M info
HRTX
Jun 16, 2026, 2:49 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.39275
Real-time Price: $0.250 info
Change: -$0.14275 (-36%) info
Market Cap: $48.044M info
HRTX
Jun 02, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.4559
Real-time Price: $0.250 info
Change: -$0.2059 (-45%) info
Market Cap: $48.044M info
HRTX
Jun 02, 2026, 5:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.460
Real-time Price: $0.250 info
Change: -$0.210 (-46%) info
Market Cap: $48.044M info
HRTX
May 11, 2026, 8:00 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.18
Real-time Price: $0.250 info
Change: -$0.930 (-79%) info
Market Cap: $48.044M info
HRTX
May 11, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.25
Real-time Price: $0.250 info
Change: -$0.997 (-80%) info
Market Cap: $48.044M info
HRTX
Apr 30, 2026, 2:09 PM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $1.21
Real-time Price: $0.250 info
Change: -$0.955 (-79%) info
Market Cap: $48.044M info
HRTX
Apr 30, 2026, 2:09 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $1.21
Real-time Price: $0.250 info
Change: -$0.955 (-79%) info
Market Cap: $48.044M info
HRTX
Apr 20, 2026, 5:13 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.250 info
Change: -$0.800 (-76%) info
Market Cap: $48.044M info
HRTX
Apr 06, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.820
Real-time Price: $0.250 info
Change: -$0.570 (-70%) info
Market Cap: $48.044M info
HRTX
Feb 26, 2026, 8:06 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $1.14
Real-time Price: $0.250 info
Change: -$0.8868 (-78%) info
Market Cap: $48.044M info
HRTX
Feb 26, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $0.250 info
Change: -$0.830 (-77%) info
Market Cap: $48.044M info
HRTX
Jan 09, 2026, 1:08 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.48
Real-time Price: $0.250 info
Change: -$1.23 (-83%) info
Market Cap: $48.044M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets